


# Oxford Gene Technology — NGS Survey 2013




**596** researchers working with NGS responded to our survey to find out their current use and future demands from the market — with interesting results. For each survey completed, a donation was made to DEBRA (UK charity for the genetic skin blistering condition Epidermolysis Bullosa).

## Response rate (%) per country




## Type of organisation



The majority of the respondents are located in the UK and US working in an academic organisation.

## Most popular NGS methods — Your top choices

Targeted resequencing (i.e., targeted panel sequencing and exome sequencing) and RNA-seq are in high demand with 72% of respondents planning to use one of these methods in the next 12 months. Only 13% of respondents are interested in data analysis-intensive whole genome sequencing.




## Top research areas for NGS

Tying in with the interest in targeted resequencing, **cancer and rare disease** are the most popular research areas for NGS. Offering cost-effective, high-resolution analysis, targeted resequencing is a logical choice for these research areas, enabling accurate detection of rare variants.

Higher resolution also increases data accuracy and confidence, which is particularly important when developing a clinical test. This is likely to be a primary reason why over **60% of respondents look to use targeted panel resequencing** for such assays.

## Top 3 research areas




## NGS methods for clinical test



## Your preferred sequencing platform for targeted panel sequencing


Illumina platforms are revealed to be the market-leading sequencing technology for targeted panel sequencing.\*



\*Respondents were allowed multiple answers, which is why the figures do not total 100%

## Barriers to NGS usage

When asked reasons why NGS might be difficult to implement in their investigations, researchers cited bioinformatics, including data analysis and interpretation as the biggest challenges, followed by test parameters such as experimental design and sample quality.



As a consequence, over a third of researchers are choosing to outsource their data analysis to dedicated service providers for rapid access to the meaningful results they need.

**36% are outsourcing data analysis**

## What researchers want from NGS service providers

The top 3 essential factors when choosing an NGS service provider highlight a strong need for quality metrics, expert data analysis and fast delivery of results.

- **Confidence in data quality 38%**
- **Bioinformatics expertise for rapid data analysis 22%**
- **Rapid turnaround time 13%**

## About OGT

Oxford Gene Technology (OGT) is a leading genomic services provider offering flexible, comprehensive next generation whole exome, pre-designed panel, or custom panel sequencing. OGT Geneefficiency™ Genomic Services provide complete management of the process from fully optimised project and capture design through to the delivery of an intuitive, user-friendly report, providing investigators with easy access to meaningful data — without the need for in-house bioinformatics resource.

**For more information about OGT's Geneefficiency Sequencing Services visit [www.ogt.com](http://www.ogt.com) or email [contact@ogt.com](mailto:contact@ogt.com).**

**Oxford Gene Technology, Begbroke Science Park, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, UK**

T: +44(0)1865 856826 (US: 914-467-5285) E: [contact@ogt.com](mailto:contact@ogt.com) W: [www.ogt.com](http://www.ogt.com)

The OGT NGS survey was conducted in February 2013. Over 1900 researchers believed to be working within NGS were polled. The data presented here is derived from all 596 researchers that responded. The survey response data does not reflect or constitute the opinions, endorsement or position of Oxford Gene Technology or its subsidiaries. Geneefficiency NGS browser: For Research Use Only; Not for Diagnostic Procedures.

This document and its contents are © Oxford Gene Technology IP Limited – 2013. All rights reserved. OGT™ and Geneefficiency™ are trademarks of Oxford Gene Technology IP Limited.